Alterity Therapeutics (PRNAD) Invested Capital (2020 - 2025)

Alterity Therapeutics (PRNAD) has reported Invested Capital for 14 consecutive years, with -$146.4 million the latest figure, recorded in Q2 2025.

• In Q2 2025, Invested Capital fell 1.43% year-over-year to -$146.4 million; the TTM figure through Jun 2025 stood at -$146.4 million (down 1.43% YoY), while the FY2025 annual figure was -$146.4 million, down 1.43% from the prior year.
• Invested Capital came in at -$146.4 million for Q2 2025 at Alterity Therapeutics, down from -$144.4 million in the prior quarter.
• The five-year high for Invested Capital was $21.7 million in Q2 2022, with the low at -$146.4 million in Q2 2025.
• Average Invested Capital over 5 years is -$47.0 million, with a median of $12.8 million recorded in 2023.
• Across the five-year window, Invested Capital surged 549.48% in 2021 and tumbled 1231.69% in 2024, its largest moves.
• Year by year, Invested Capital stood at $21.5 million in 2021, then gained by 0.82% to $21.7 million in 2022, then plunged by 41.12% to $12.8 million in 2023, then sank by 1231.69% to -$144.4 million in 2024, then retreated by 1.43% to -$146.4 million in 2025.
• According to Business Quant data, Invested Capital over the past three periods registered -$146.4 million, -$144.4 million, and $12.8 million for Q2 2025, Q2 2024, and Q2 2023 respectively.